Otsuka Holdings Co., Ltd. is a holding company that oversees a healthcare group operating across medical, nutraceutical, consumer, and other business segments. The medical segment involves the development and sale of pharmaceuticals, including treatments for schizophrenia, bipolar disorder, cancer, and kidney diseases, with key products such as Abilify, Rexulti, Samusca, and Abraxane. Subsidiaries Otsuka Pharmaceutical and Taisho Pharmaceutical manage domestic operations, while Otsuka America Pharmaceutical, Taisho Oncology, and Otsuka Pharmaceutical Europe handle international markets in the US, Europe, and other regions. The nutraceutical segment focuses on health supplements and functional foods, featuring brands like Pocari Sweat, Oronamin C, Calorie Mate, and Soyjoy, distributed through Otsuka Pharmaceutical, Pharmabite LLC, and Deia Foods Inc. The consumer segment includes mineral water and beverages under brands such as Crystal Geyser and Ridge, managed by Otsuka Foods and CG Roxanne LLC. Additional operations include chemical manufacturing by Otsuka Chemical, measurement instruments by Otsuka Electronics, and warehousing services by Otsuka Warehouse.

Summarised from the annual report, fiscal year ended Dec 2025

Industry Drug Manufacturers - General Homepage otsuka.com
Sector Healthcare IR page otsuka.com/jp/ir
Tags
pharmaceuticals, nutraceuticals, functional foods, mineral water, oncology, psychiatry, nephrology, clinical nutrition, health supplements, beverages, Otsuka Pharmaceutical, Taisho Pharmaceutical, Otsuka America Pharmaceutical, Taisho Oncology, Otsuka Pharmaceutical Europe, Otsuka Pharmaceutical D&C, Pharmabite LLC, Deia Foods Inc, PT Amerta Indah Otsuka, Nutrition et Sante SAS, Otsuka Foods, CG Roxanne LLC, Alma S.A., Otsuka Chemical, Otsuka Electronics, Otsuka Packaging Industry, Otsuka Techno, Otsuka Warehouse, Abilify, Rexulti, Samusca, Jynarque, Lonsurf, Abraxane, Aloxi, Nuedexta, Mizelt, INQOVI, Vilanoa, VOYXACT, Pocari Sweat, Oronamin C, Thiovita, Body Mente, OS-1, Deia, Gelbre, Exel, Bonafide, Yucora, Inner Signal, Sakura, Nature Made, Mega Food, Calorie Mate, Soyjoy, Crystal Geyser, Symbiyo, Matcha, Ridge, Bon Curry, My Size
Press page —

Metrics

Valuation  
Market cap ¥ 6.19T
Market cap (USD) $ 38.688B
P/E 15.48
PEG 0.39
P/BV 1.88
P/S 2.30
P/OCF 15.34
P/FCF 23.63
Dividend yield 1.2%
Turnover / mcap —
Returns  
ROE 12.4%
ROI 11.3%
ROIC 11.6%
Profit margin 14.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 39.4%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 47.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011
Revenue 2.469T 2.33T 2.019T 1.738T 1.498T 1.423T 1.396T 1.292T 1.24T 1.214T 1.445T 1.224T 1.453T 1.218T 1.155T
Net profit 363.15B 343.12B 121.616B 134.019B 125.463B 148.137B 127.151B 82.492B 112.492B 85.785B 84.086B 143.143B 150.989B 122.429B 92.174B
Free cash flow 261.91B 225.276B 168.559B 104.061B 115.712B 134.964B 129.197B — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011
Share price 8.886K 8.613K 5.289K 4.315K 4.164K 4.423K 4.878K 4.491K 4.946K 5.099K 4.315K 3.619K 3.089K 3.305K 2.447K
Price performance 12m 0.03 0.63 0.23 0.04 -0.06 -0.09 0.09 -0.09 -0.03 0.18 0.19 0.17 -0.07 0.35 —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (JPY) — — 65.9B 50B 28.7B 32.9B 26.4B 69.4B 7.35B 39.2B
Borrowings, non-current (JPY) — — 140B 136B 125B 103B 93.8B 69.2B 87.3B 87.9B
Lease liabilities (JPY) — — — 66.8B 72.8B 76.8B 73.9B 75.6B 94.8B 101B
Cash and deposits (JPY) 370B 337B 285B 334B 357B 411B 472B 513B 426B 535B
Intangible assets (JPY) — — 488B 479B 457B 523B 580B 491B 544B 574B
Net debt (borrowings + leases - cash) (JPY) — — -79.1B -148B -131B -198B -277B -299B -237B -307B
Cash flow detail
Operating cash flow (JPY) 126B 103B 136B 193B 233B 229B 212B 283B 355B 404B
Purchases of property, plant and equipment (JPY) — — -57.1B -48.6B -48.8B -52.5B -60.9B -90.7B -95.6B -87.8B
Purchases of intangible assets (JPY) — — -16.5B -14.8B -49.1B -60.7B -46.8B -23.9B -33.8B -53.8B
Change in inventories (cash effect) (JPY) — — -17.4B -2.85B -19.2B 6.51B -21.7B -16.6B -38.6B -53.5B
Dividends paid (cash effect) (JPY) — — -55.3B -55.6B -55.7B -56B -55.6B -55.7B -66.8B -71B
Share buybacks (cash effect) (JPY) — — -1M -1M -1M -1M 0.00 -1M -50B -70.1B
Interest paid (cash effect) (JPY) — — -2.97B -4.19B -3.2B -2.66B -3.46B -3.21B -6.46B -4.57B
Free cash flow (OCF - PPE - intangibles) (JPY) — — 62.2B 129B 135B 116B 104B 169B 225B 262B
Income detail
Research and development expense (JPY) — — 193B 216B 217B 232B 275B 308B 314B 353B
↳ 5y CAGR +9.8% +7.8% +10.2%
Total comprehensive income (JPY) 30.1B — 36.9B 119B 143B 217B 272B 228B 460B 444B
Comprehensive income to owners (JPY) 65.7B 135B 35.4B 115B 139B 212B 268B 223B 456B 439B
Segments
Consumer Products · Segment revenue (JPY) — — 33.8B 33.6B 31.4B 31.9B 35.9B 37.1B 33.8B 34.6B
↳ YoY growth -0.8% -6.5% +1.8% +12.4% +3.3% -9.0% +2.6%
Consumer Products · Segment operating income (JPY) — — 8.67B 8.85B 10.8B 5.31B 6.93B 11.9B 23B 25.2B
Nutraceuticals · Segment revenue (JPY) — — 339B 334B 334B 377B 437B 483B 557B 578B
↳ YoY growth -1.5% +0.1% +12.7% +16.0% +10.6% +15.2% +3.7%
Nutraceuticals · Segment operating income (JPY) — — 43B 39.2B 41.5B 46.6B 56.3B 33.6B 59.8B 57.7B
Other · Segment revenue (JPY) — — 141B 144B 140B 150B 169B 176B 114B 116B
↳ YoY growth +1.8% -2.6% +7.0% +12.8% +4.2% -35.6% +2.0%
Other · Segment operating income (JPY) — — 9.88B 10.9B 13B 11.4B 11.9B 3.89B 7.53B 7.98B
Pharmaceuticals · Segment revenue (JPY) — — 817B 924B 955B 978B 1.14T 1.36T 1.63T 1.74T
↳ YoY growth +13.1% +3.3% +2.3% +16.4% +19.9% +19.4% +7.1%
Pharmaceuticals · Segment operating income (JPY) — — 84.8B 161B 177B 137B 123B 141B 285B 445B
Reported Mar 31, 2017 Mar 30, 2018 Mar 30, 2020 Mar 31, 2021 Mar 31, 2021 Mar 31, 2022 Mar 31, 2023 Mar 29, 2024 Mar 31, 2025 Mar 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

(会社法第 459 条第 1 項の規定による定款の定めに基づく自己株式の取得および会社法第 178 条の規定 に基づく自己株式の消却) 当社は、会社法第 459 条第 1 項の規定に基づく自己株式の取得について、2026 年2月 13 日開催の当社 取締役会決議に基づき、下記の通り実施し、これをもって終了いたしましたので、お知らせいたします。 なお、同取締役会において決議しました、会社法第 178 条の規定に基づく自己株式の消却につきまして は、消却する株式の数が確定いたしましたので、併せてお知らせいたします。 記

  1. 2026 年 10 月 1 日~2026 年 10 月 28 日期間の取得状況 (1)取得した株式の種類

当社普通株式

(2)取得価額の総額

2,958,635,000 円

(3)取得した株式の総数

254,200 株

(4)取得期間

2026 年 10 月1日~2026 年 10 月 28 日

(5)取得方法

東京証券取引所における市場買付

  1. 自己株式の取得結果 (1)取得した株式の種類

当社普通株式

(2)取得価額の総額

49,994,398,554 円

(3)取得した株式の総数

4,537,700 株

(4)取得期間

2026 年2月 16 日~2026 年 10 月 28 日

(5)取得方法

東京証券取引所における市場買付

  1. 自己株式の消却 (1)消却する株式の種類

当社普通株式

(2)消却する株式の総数

4,537,700 株 (消却前発行済株式総数に対する割合 0.84%)

(3)消却後の発行済株式総数

538,451,217 株

(4)消却予定日

2026 年 12 月 11 日

(ご参考)

  1. 自己株式の取得に関する決議内容(2026 年2月 13 日開催取締役会) (1)取得対象株式の種類

当社普通株式

(2)取得しうる株式の総数

700 万株(上限) (発行済株式総数(自己株式を除く)に対する割合

(3)株式の取得価格の総額

500 億円(上限)

(4)取得期間

2026 年2月 16 日から 2026 年 12 月 23 日まで

1.33%)

  1. 自己株式の消却に関する決議内容(2026 年2月 13 日開催取締役会) (1)消却する株式の種類

当社普通株式

(2)消却する株式の数

上記1により取得した自己株式全数

(3)消却予定日

2027 年1月 29 日

Prompts

Otsuka Holdings Co., Ltd. (ticker 4578), listed in Japan.

ETFs Holding Otsuka Holdings Co., Ltd.

ETF Weight in ETF Shares Market value As of
DSTX 0.97% 6,900 $ 458.726K Jun 30, 2026
UMMA 0.36% 14,013 $ 1.075M Aug 31, 2026
IVSI 0.17% 200 $ 13.291K Jun 30, 2026
NTSI 0.16% 12,000 $ 797.785K Jun 30, 2026
DFAI 0.11% 271,600 $ 20.833M Nov 12, 2026
FLSP 0.10% 13,800 $ 917.453K Jun 30, 2026
AVSD 0.09% 4,200 $ 327.503K Nov 16, 2026
DFIC 0.09% 176,700 $ 13.554M Nov 12, 2026
AVDE 0.07% 177,400 $ 13.833M Nov 16, 2026
DFAX 0.05% 84,400 $ 6.474M Nov 12, 2026
DXIV 0.03% 1,000 $ 76.704K Nov 12, 2026
DFSI 0.03% 4,100 $ 314.487K Nov 12, 2026